the pharma major has launched the drug-free, non-invasive migraine management wearable device nerivio in germany through its step-down subsidiary betapharm. nerivio is approved by the united states food and drug administration (usfda) and is ce-mark-certified in europe. last year, the company entered into an exclusive agreement with theranica for the marketing and distribution of nerivio in multiple markets.
MARKET VIEW
OUTLOOK
SECTORS
STRATEGY
VIEW
PERSONAL FINANCE
INSURANCE
INVEST
MUTUAL FUND
GENERAL